임상 한눈에 보기

• 31건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 3 · Phase 2 · Phase 1 · Phase 1, Phase 2…
• Status: Completed · Unknown status · Terminated
• 주요 endpoint: Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event · Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events · Version 4.0 (NCI-CTCAE v4.0) · Number of Participants Who Died Over the Course of the Study by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term) · Number of Participants Who Died Within 6 Months of Starting Study Treatment by Reported Cause of Death (Adverse Events Leading to Death by System Organ Class and Preferred Term)
• 등록된 결과: ORR 79.5%
• PFS: 20.67
• 핵심: This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in co…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.